Millennium Management LLC Grows Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Millennium Management LLC lifted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 56.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,065,508 shares of the company’s stock after acquiring an additional 383,634 shares during the quarter. Millennium Management LLC owned approximately 1.25% of Syndax Pharmaceuticals worth $21,875,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. nVerses Capital LLC purchased a new position in Syndax Pharmaceuticals during the 2nd quarter worth $33,000. CANADA LIFE ASSURANCE Co grew its position in shares of Syndax Pharmaceuticals by 28.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock worth $171,000 after buying an additional 1,587 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock valued at $187,000 after buying an additional 1,312 shares during the period. EntryPoint Capital LLC lifted its stake in Syndax Pharmaceuticals by 487.1% in the first quarter. EntryPoint Capital LLC now owns 8,636 shares of the company’s stock worth $206,000 after acquiring an additional 7,165 shares during the period. Finally, Seven Eight Capital LP purchased a new stake in Syndax Pharmaceuticals in the first quarter worth about $229,000.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $18.82 on Friday. The business has a fifty day moving average of $19.69 and a 200 day moving average of $20.85. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $25.34. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -5.84 and a beta of 0.91.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.11. The firm had revenue of $3.50 million during the quarter. The firm’s revenue was up 3499999990.0% on a year-over-year basis. During the same period last year, the firm posted ($0.64) EPS. As a group, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on SNDX shares. Stifel Nicolaus boosted their price target on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 26th. Barclays upped their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. Citigroup lifted their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Scotiabank cut Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, Jefferies Financial Group initiated coverage on Syndax Pharmaceuticals in a research note on Friday, June 28th. They issued a “buy” rating and a $37.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $35.30.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).